These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3488021)

  • 41. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents.
    Jorgensen JH; Doern GV; Thornsberry C; Preston DA; Redding JS; Maher LA; Tubert T
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):27-32. PubMed ID: 3259490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beta-lactam susceptibility of Haemophilus influenzae strains showing reduced susceptibility to cefuroxime.
    James PA; Hossain FK; Lewis DA; White DG
    J Antimicrob Chemother; 1993 Aug; 32(2):239-46. PubMed ID: 8226426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013.
    Skaare D; Anthonisen IL; Kahlmeter G; Matuschek E; Natås OB; Steinbakk M; Sundsfjord A; Kristiansen BE
    Euro Surveill; 2014 Dec; 19(49):. PubMed ID: 25523969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The permeability barrier of Haemophilus influenzae type b against beta-lactam antibiotics.
    Coulton JW; Mason P; Dorrance D
    J Antimicrob Chemother; 1983 Nov; 12(5):435-49. PubMed ID: 6608514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serotype distribution and beta-lactam resistance in Haemophilus influenzae isolated from patients with respiratory infections in Korea.
    Bae S; Lee J; Kim E; Lee J; Yu J; Kang Y
    J Microbiol; 2010 Feb; 48(1):84-8. PubMed ID: 20221734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae.
    Stein GE; Schooley S; Walker RD; Strenkoski-Nix L
    Pharmacotherapy; 1997; 17(2):235-41. PubMed ID: 9085313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of beta-lactam resistance in Haemophilus influenzae.
    Gutmann L; Williamson R; Collatz E; Acar JF
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):610-5. PubMed ID: 3143572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
    Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
    Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiation of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae from other H. influenzae strains by a disc method.
    Ubukata K; Chiba N; Hasegawa K; Shibasaki Y; Sunakawa K; Nonoyama M; Iwata S; Konno M
    J Infect Chemother; 2002 Mar; 8(1):50-8. PubMed ID: 11957120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of cephalosporin antibiotics against Haemophilus influenzae.
    Philpott-Howard J; Williams JD
    Scand J Infect Dis Suppl; 1983; 39():109-11. PubMed ID: 6606223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility of Haemophilus influenzae isolates collected from 4 centers in Brazil (1990-2003).
    de Almeida AE; de Filippis I; Ferreira DG; de Abreu AO; Rebelo C; Gemal AL; Marzochi KB
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):57-62. PubMed ID: 16290031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
    Pichichero ME; Doern GV; Kuti JL; Nicolau DP
    Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The activity of Sch 29482 against type b Haemophilus influenzae lacking or possessing detectable beta-lactamase activity.
    Wong K; Roberts MC; Smith AL
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():163-70. PubMed ID: 6977529
    [No Abstract]   [Full Text] [Related]  

  • 55. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999.
    Marco F; García-de-Lomas J; García-Rey C; Bouza E; Aguilar L; Fernández-Mazarrasa C;
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3226-8. PubMed ID: 11600386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1992; 38(1):7-13. PubMed ID: 1618006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998.
    Zhanel GG; Karlowsky JA; Low DE; Hoban DJ
    J Antimicrob Chemother; 2000 May; 45(5):655-62. PubMed ID: 10797089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.
    Barry AL; Fuchs PC; Pfaller MA
    Antimicrob Agents Chemother; 1993 Jan; 37(1):14-8. PubMed ID: 8431012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antimicrobial activities of beta-lactam antibiotics against clinically isolated Haemophilus influenzae].
    Takahashi T; Tsujihara Y; Harada M; Shimura H; Takahashi S; Hachiya K; Matsumoto F; Takahashi S
    Jpn J Antibiot; 1999 Apr; 52(4):292-301. PubMed ID: 10396686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of BMY-28100, a new oral cephalosporin.
    Eliopoulos GM; Reiszner E; Wennersten C; Moellering RC
    Antimicrob Agents Chemother; 1987 Apr; 31(4):653-6. PubMed ID: 3496846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.